Our mission at NAVERIS is to deliver innovations in technology with the potential to transform cancer detection, drug development, and clinical trials.
Early detection of malignant cancers is critical to ensuring that tumors can be effectively treated with a favorable prognosis for patients. To this end, we are developing several related technologies with the potential to offer highly sensitive and specific cancer detection through blood analysis. Our flagship technology is a liquid biopsy blood test that analyzes tumor DNA in the circulation to detect specific subtypes of cancer. In clinical studies, this test has established its ability to detect cancers early – in many cases months before patients would be symptomatic given current clinical practice.
Complementing these efforts, we are also leveraging innovations in 3D biomimetic technology to provide more accurate ex vivo models for every stage of drug development – ranging from target ID & HTS to lead optimization & validation.
Our 3D biomimetic technology replicates the morphological, signaling and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, our technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.
Early detection of malignant cancers is critical to ensuring that tumors can be effectively treated with a favorable prognosis for patients. To this end, we are developing several related technologies with the potential to offer highly sensitive and specific cancer detection through blood analysis. Our flagship technology is a liquid biopsy blood test that analyzes tumor DNA in the circulation to detect specific subtypes of cancer. In clinical studies, this test has established its ability to detect cancers early – in many cases months before patients would be symptomatic given current clinical practice.
Complementing these efforts, we are also leveraging innovations in 3D biomimetic technology to provide more accurate ex vivo models for every stage of drug development – ranging from target ID & HTS to lead optimization & validation.
Our 3D biomimetic technology replicates the morphological, signaling and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, our technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.
Location: United States, Massachusetts, Natick
Employees: 11-50
Total raised: $51M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | BrightEdge | brightedge... |
| - | Transolam | transolam.... |
| - | Gurnet Poi... | gurnetpoin... |
| - | BrightEdge | acsbrighte... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.09.2022 | Series A | $51M | - |
Mentions in press and media 5
| Date | Title | Description |
| 27.09.2022 | Naveris Raises $33.4M in Expansion of Series A | Naveris, a Natick, MA-based commercial-stage life sciences company, raised $33.4M in expansion of Series A funding. The round, which brought total funding to $51m, was led by Gurnet Point Capital, with participation from TechU Ventures and ... |
| 21.09.2022 | Naveris Raises $51M for Early Detection of Viral-Driven Cancers | What You Should Know: Founded in 2017, Naveris is a privately held biotechnology company with facilities in Massachusetts and North Carolina. The company’s mission is to improve outcomes for the millions of people at risk of developing vira... |
| 19.09.2022 | Naveris Raises $51M Series A | NATICK, MA, Naveris, Inc., a commercial-stage life sciences company, announced a $33.4 million expansion of its Series A financing. >> Click here for more funding data on Naveris >> To export Naveris funding data to PDF and ... |
| - | Naveris | “Naveris develops highly sensitive blood tests that identify viral cancers significantly earlier than scans or traditional biopsies.” |
| - | Naveris | “Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.” |